American Society of Clinical Oncology (ASCO) 2022
We look forward to meeting with you at ASCO.
Request a consultation with our medical imaging experts in Chicago to learn how we help our clients reduce risk to key areas of clinical development. Our nearly five decades of experience has honed our skills and capabilities in clinical trials ranging from small, early-phase molecular imaging studies to large, more complex, late-phase registrational studies.
Clario leads the industry with over 1,400 oncology trials and more than 100 FDA oncology approvals.
Clario’s independent reviewers have experience with the latest advancements in tumor response criteria, imaging modalities, and oncology biomarkers. This expertise helps ensure an innovative approach and world-class support for oncology clinical trials with imaging endpoints.
Our team of in-house board-certified, sub-specialty trained radiologists, nuclear physicians and medical oncologists can analyze all images from baseline through follow-up with fast turnaround times. Clario clients look to them to provide a blinded, comprehensive oncology response review in these areas:
- Immuno-Oncology: Clario experts understand established assessment criteria and have extensive expertise applying approaches such as iRECIST and irRECIST.
- Cardio-Oncology: Clario supports cardiac safety studies by facilitating risk assessment for oncology drugs early in clinical development.
- Molecular Imaging Expertise: Clario supports a full range of molecular imaging modalities to identify, stage and monitor various cancers.
Stop by booth #28135 and speak with our experts about how the combination of world-class scientific expertise, outstanding project management, and superior regulatory insight can expedite your oncology drug development. Or fill out our contact form and request “Imaging Oncology” and an expert will reach out to schedule a meeting.
